MedTrace Logo

Phase II Image Guided Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer

NCT02262000 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2021-01-22

Study results available
· View outcomes & findings →

Summary

This study will help researchers learn about the best dose of radiation to be used when treating large early stage non-small cell lung cancer (NSCLC) with a treatment called stereotactic ablative radiotherapy (SABR). Current treatments with SABR for early stage NSCLC show positive response. But, for large early stage NSCLC it may be better to give different SABR doses than what is used in routine early stage NSCLC treatment. It is not understood which dose is best for treating large early stage NSCLC. Therefore, this study can help researchers learn if giving a higher dose using SABR over a period of 5-10 treatment days can increase the chance of cure for large early stage NSCLC.

Conditions

  • Non Small Cell Lung Cancer

Interventions

RADIATION

Image Guided Stereotactic Ablative Radiotherapy

Sponsors & Collaborators

  • American Cancer Society, Inc.

    collaborator OTHER

  • West Virginia University

    lead OTHER

Principal Investigators

  • Malcolm Mattes, MD · West Virginia University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2016-07-07
Completion
2017-07-10

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02262000 on ClinicalTrials.gov